{
    "clinical_study": {
        "@rank": "4775", 
        "arm_group": [
            {
                "arm_group_label": "Primary hyperparathyroidism", 
                "arm_group_type": "Experimental", 
                "description": "Subjects with biochemical evidence, including elevated serum calcium and PTH levels, of primary hyperparathyroidism. All patients will undergo 11C-methionine PET/CT, SPECT-CT and 18F-FDG PET/CT scanning."
            }, 
            {
                "arm_group_label": "Tertiary hyperparathyroidism", 
                "arm_group_type": "Experimental", 
                "description": "Patients with biochemical evidence, including elevated serum calcium, PTH and creatinine levels, of tertiary hyperparathyroidism. All patients will undergo 11C-methionine PET/CT, SPECT-CT and 18F-FDG PET/CT scanning."
            }
        ], 
        "brief_summary": {
            "textblock": "The overall sensitivity and specificity of 11C-MET PET/CT is superior to 18F-FDG PET/CT and\n      conventional SPECT-CT for the detection of abnormal parathyroid glands."
        }, 
        "brief_title": "11C Methionine PET for the Detection of Hyperfunctional Parathyroid Tissues", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Primary Hyperparathyroidism", 
            "Tertiary Hyperparathyroidism"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hyperparathyroidism", 
                "Hyperparathyroidism, Primary"
            ]
        }, 
        "detailed_description": {
            "textblock": "STUDY OBJECTIVES Primary: To compare the accuracy, sensitivity and specificity of\n      11C-methionine (MET) PET/CT and 99mTc-MIBI SPECT-CT in the detection of pathologic\n      parathyroid glands in patients with primary or tertiary hyperparathyroidism.\n\n      Secondary:To compare the accuracy, sensitivity and specificity of 11C-MET and 18F-FDG PET/CT\n      scans in the detection of pathologic parathyroid glands in patients with primary or tertiary\n      hyperparathyroidism.\n\n      STUDY DESIGN A phase II diagnostic imaging, single-centre study to compare the accuracy of\n      11C-MET PET/CT with standard 99mTc-MIBI SPECT-CT and with 18F-FDG PET/CT imaging in patients\n      with primary or tertiary hyperparathyroidism.\n\n      STUDY POPULATION Number of Subjects: 50 patients Number of groups: 2: 25 with primary\n      hyperparathyroidism, 25 with tertiary hyperparathyroidism.\n\n      Age/Gender: Age greater than or equal to 19 years / Male and Female Study specific\n      requirements: Subjects with clinically suspected primary or tertiary hyperparathyroidism who\n      require 99mTc-MIBI SPECT-CT parathyroid imaging.\n\n      INVESTIGATIONAL PRODUCT Product: 11C-Methionine Route of administration: Intravenous\n      Dosage(s) and frequency: Radioactive dose of 11C-Methionine of 6 MBq per kilogram body\n      weight per injection (maximum dose of 555 MBq); one injection per patient.\n\n      COMPARATOR PRODUCTS Product: 99mTc-Methoxyisobutylisonitrite; 18F-Fluorodeoxyglucose Route\n      of administration: Intravenous Dosage(s) and frequency: (1) Radioactive dose of\n      99mTc-Methoxyisobutylisonitrite of 555 - 740 MBq per injection; one injection per patient.\n      (2) Radioactive dose of 18F-Fluorodeoxyglucose of 296 - 521 MBq per injection; one injection\n      per patient.\n\n      EVALUATION CRITERIA Efficacy: The comparison of the accuracy, sensitivity, and specificity\n      of 11C-MET PET/CT with 99mTc-MIBI SPECT-CT and 18F-FDG PET/CT in the detection of pathologic\n      parathyroid glands in patients with primary or tertiary hyperparathyroidism.\n\n      Safety: Vital signs before and following 11C-MET administration; adverse events collection."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults > age 18;\n\n          -  Able to provide written informed consent;\n\n          -  Subjects with biochemical evidence, including elevated serum calcium and PTH levels,\n             of primary hyperparathyroidism;\n\n          -  Patients with biochemical evidence, including elevated serum calcium, PTH and\n             creatinine levels, of tertiary hyperparathyroidism.\n\n        Exclusion Criteria:\n\n          -  Subjects with previous successful parathyroidectomy and parathyroid tissue\n             reimplantation;\n\n          -  Pregnancy;\n\n          -  Subjects who are unable to tolerate the physical/logistical requirements of\n             completing two PET/CT scans, including lying still for a prolonged period of time and\n             receiving two intravenous injections.\n\n          -  Subjects who exceed the safe weight limit of the PET/CT bed (204.5 kg) or who cannot\n             fit through the PET/CT machine (diameter 70cm)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01783002", 
            "org_study_id": "H12-01220"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Primary hyperparathyroidism", 
                    "Tertiary hyperparathyroidism"
                ], 
                "description": "PET with the radiopharmaceutical carbon-11 methionine (11C-MET) has been considered to improve diagnosis due to a superior spatial resolution and higher specificity compared to other radiotracers such as 18F-FDG. For the 11C-MET PET/CT, the patient will receive an intravenous bolus injection of 11C-MET as manufactured at the BCCA production facility at a dose of 6 (0.16 mCi) MBq per kilogram but not to exceed 555 MBq (15 mCi).", 
                "intervention_name": "11C-Methionine PET/CT scanning", 
                "intervention_type": "Radiation", 
                "other_name": "11C-MET"
            }, 
            {
                "arm_group_label": [
                    "Primary hyperparathyroidism", 
                    "Tertiary hyperparathyroidism"
                ], 
                "description": "For PET/CT scans, the patient will first receive an intravenous bolus injection of 18F-FDG as manufactured at the BCCA production facility in a dose determined by body weight but not to exceed 521 MBq (14.1 mCi).  Our standard adult prescription (70kg adult) for 18F-FDG is 296 MBq (8.0 mCi). The target dose for body scans is increased by 59.2 MBq (1.6 mCi) for every 20 kg increase in body weight to a maximum target dose of 474 MBq (12.8 mCi).", 
                "intervention_name": "18F-FDG PET/CT scanning", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": [
                    "Primary hyperparathyroidism", 
                    "Tertiary hyperparathyroidism"
                ], 
                "description": "For the SPECT-CT scan, each injection of intravenous 99mTc-MIBI is dosed at a maximum of 20 mCi (740MBq), as per usual standard of care.  The energy window of each scan is at 140 keV, consistent with the standard of SPEC-CT imaging techniques.", 
                "intervention_name": "SPECT-CT scanning", 
                "intervention_type": "Radiation"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 31, 2013", 
        "location": [
            {
                "contact": {
                    "email": "jrlin13@gmail.com", 
                    "last_name": "Rui Jun Lin, MD", 
                    "phone": "6045619854"
                }, 
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V5Z 1M9"
                    }, 
                    "name": "Vancouver General Hospital"
                }, 
                "investigator": {
                    "last_name": "Donald W Anderson, MD, FRCRC", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "tparhar@bccancer.bc.ca", 
                    "last_name": "Tarnjit Parhar", 
                    "phone": "604-877-6000", 
                    "phone_ext": "2818"
                }, 
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V5Z 4E6"
                    }, 
                    "name": "British Columbia Cancer Agency"
                }, 
                "investigator": {
                    "last_name": "Donald Wilson, MD, FRCPC", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pre-operative Parathyroid Imaging: a Comparison of 11C-Methionine PET, 18F-FDG PET AND SPEC-CT for the Detection of Hyperfunctional Parathyroid Tissues", 
        "overall_contact": {
            "email": "jrlin13@gmail.com", 
            "last_name": "Rui Jun Lin, MD", 
            "phone": "604-561-9854"
        }, 
        "overall_contact_backup": {
            "email": "tparhar@bccancer.bc.ca", 
            "last_name": "Tarnjit Parhar", 
            "phone": "604-877-6000", 
            "phone_ext": "2818"
        }, 
        "overall_official": [
            {
                "affiliation": "University of British Columbia; Vancouver General Hospital", 
                "last_name": "Donald W Anderson, MD, FRCSC", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "British Columbia Cancer Agency", 
                "last_name": "Donald Wilson, MD, FRCPC", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Sensitivity is the percentage of patients that were correctly identified to have an abnormal parathyroid gland by the imaging studies.", 
                "measure": "To compare the sensitivity of 11C-MET PET/CT, SPECT-CT and 18F-FDG PET/CT in the detection of pathologic parathyroid glands in patients with primary or tertiary hyperparathyroidism", 
                "safety_issue": "No", 
                "time_frame": "Patient will undergo the scans at baseline"
            }, 
            {
                "description": "Specificity is defined as the percentage of patients that were correctly rejected for having an abnormal parathyroid gland by the imaging studies.", 
                "measure": "To compare the specificity of11C-MET PET/CT, SPECT-CT and 18F-FDG PET/CT in the detection of pathologic parathyroid glands in patients with primary or tertiary hyperparathyroidism", 
                "safety_issue": "No", 
                "time_frame": "Patient will undergo the scans at baseline"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01783002"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of British Columbia", 
            "investigator_full_name": "Donald W. Anderson", 
            "investigator_title": "Clinical professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "All adverse events will be recorded. An Adverse Event (AE) is any untoward, undesired, unplanned medical occurrence in a participant and does not necessarily have a causal relationship with the study intervention. Expected adverse events from PET/CT scans include bruising, bleeding or infection at the site of intravenous radiotracer injection. Other expected adverse events include feeling of discomfort or claustrophobia from being in the scanner.", 
            "measure": "To evaluate the safety profile of 11C-MET PET/CT.", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 2 weeks"
        }, 
        "source": "University of British Columbia", 
        "sponsors": {
            "collaborator": {
                "agency": "British Columbia Cancer Agency", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of British Columbia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}